GDRX vs. RNG, FIVN, DADA, TOST, RDDT, GLOB, BILI, MARA, PEGA, and STNE
Should you be buying GoodRx stock or one of its competitors? The main competitors of GoodRx include RingCentral (RNG), Five9 (FIVN), Dada Nexus (DADA), Toast (TOST), Reddit (RDDT), Globant (GLOB), Bilibili (BILI), Marathon Digital (MARA), Pegasystems (PEGA), and StoneCo (STNE).
RingCentral (NYSE:RNG) and GoodRx (NASDAQ:GDRX) are both mid-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
GoodRx has lower revenue, but higher earnings than RingCentral. GoodRx is trading at a lower price-to-earnings ratio than RingCentral, indicating that it is currently the more affordable of the two stocks.
RingCentral has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.
98.6% of RingCentral shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 6.8% of RingCentral shares are held by company insiders. Comparatively, 4.2% of GoodRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, GoodRx had 9 more articles in the media than RingCentral. MarketBeat recorded 15 mentions for GoodRx and 6 mentions for RingCentral. GoodRx's average media sentiment score of 1.05 beat RingCentral's score of 0.30 indicating that RingCentral is being referred to more favorably in the media.
GoodRx has a net margin of -0.86% compared to GoodRx's net margin of -6.18%. RingCentral's return on equity of 3.45% beat GoodRx's return on equity.
RingCentral presently has a consensus target price of $39.28, indicating a potential upside of 14.85%. GoodRx has a consensus target price of $9.11, indicating a potential upside of 15.70%. Given RingCentral's stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than RingCentral.
RingCentral received 843 more outperform votes than GoodRx when rated by MarketBeat users. Likewise, 73.17% of users gave RingCentral an outperform vote while only 38.01% of users gave GoodRx an outperform vote.
Summary
GoodRx beats RingCentral on 11 of the 19 factors compared between the two stocks.
Get GoodRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
